Hasskarl Jens
Department of Hematology and Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, 79102, Freiburg, Germany.
Recent Results Cancer Res. 2010;184:61-70. doi: 10.1007/978-3-642-01222-8_5.
Sorafenib (BAY 43-9006, Nexavar) is a novel oral kinase inhibitor that targets multiple tyrosine kinases in vivo and in vitro. Main targets are receptor tyrosine kinase pathways frequently deregulated in cancer such as the raf-ras pathway, vascular endothelial growth factor (VEGF) pathway, and FMS-like tyrosine kinase 3 (FLT3). Sorafenib was approved by the FDA in fast track for advanced renal cell cancer and hepatocellular cancer and shows good clinical activity in thyroid cancer. Multiple clinical trials are undertaken to further investigate the role of sorafenib alone or in combination for the treatment of various tumor entities.
索拉非尼（BAY 43-9006，多吉美）是一种新型口服激酶抑制剂，在体内和体外均可靶向多种酪氨酸激酶。主要靶点是癌症中经常失调的受体酪氨酸激酶途径，如raf-ras途径、血管内皮生长因子（VEGF）途径和FMS样酪氨酸激酶3（FLT3）。索拉非尼已被美国食品药品监督管理局（FDA）以快速通道批准用于晚期肾细胞癌和肝细胞癌，并且在甲状腺癌中显示出良好的临床活性。正在进行多项临床试验，以进一步研究索拉非尼单独使用或联合使用在治疗各种肿瘤实体中的作用。
